KALA BIO
KALA
64 hedge funds and large institutions have $300M invested in KALA BIO in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 9 reducing their positions, and 8 closing their positions.
338% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $238K
189% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 9
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
19% more funds holding
Funds holding: 54 → 64 (+10)
5.13% more ownership
Funds ownership: 72.25% → 77.38% (+5.1%)
8% less capital invested
Capital invested by funds: $328M → $300M (-$27.2M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$16.3M |
| 2 |
Millennium Management
New York
|
+$13.6M |
| 3 |
BC
Broadfin Capital
New York
|
+$10.4M |
| 4 |
BlackRock
New York
|
+$4.06M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$3.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.2M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$10.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$7.94M |
| 4 |
Neuberger Berman Group
New York
|
-$4.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.42M |
KALA Hedge Fund Activity: Q1 2018 in Review
64 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q1 2018, worth a combined $300M — down 8.3% from $328M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KALA positions and 8 closed out — a net gain of 10 holders — while 26 added to existing stakes and 9 trimmed.
The largest buyer was OrbiMed, adding an estimated $16.3M. The largest seller was Wellington Management Group, cutting an estimated $13.2M.
- 64 institutional investors held KALA BIO (KALA) as of Q1 2018, up from 54 in Q4 2017.
- Funds reported $300M of KALA BIO stock for Q1 2018, down 8.3% quarter-over-quarter.
- 18 funds opened new KALA BIO positions in Q1 2018 and 8 closed out, a net change of +10 holders.
- The largest KALA BIO buyer in Q1 2018 was OrbiMed, an estimated $16.3M added.
- The largest KALA BIO seller in Q1 2018 was Wellington Management Group, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2018.